Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 16-week multicenter retrospective study
- 21 April 2024
- journal article
- letter
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 91 (2) , 359-361
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Bimekizumab versus Adalimumab in Plaque PsoriasisNew England Journal of Medicine, 2021
- Bimekizumab versus Secukinumab in Plaque PsoriasisNew England Journal of Medicine, 2021
- Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trialThe Lancet, 2021
- Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trialThe Lancet, 2021